The EU approval is based on positive results from the landmark DAPA-HF phase III trial, published in The New England Journal of Medicine (DOI: 10.1056/NEJMoa1911303) and follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Dapagliflozin is the first SGLT2 inhibitor to have shown a statistically significant reduction in the risk of the composite of cardiovascular death or worsening of heart failure events, including hospitalisation for HF.
September 2018 doi:10.5837/bjc.2018.s11
Importance of UK collaboration with the EU The partnerships between the UK and other EU Member States significantly increase the impact and influence of the EU’s science and research activity. When collaborating with the UK, the share of EU co-authored publications in the top 10% of highly cited publications in medical and health research is higher.2 The UK is also a top five collaboration partner for each of the other 27 Member States,3 and contributed almost 20% of the total research work carried out within EU health programmes between 2007–2016.2 European collaboration is particularly important in some fields – stratified medicine a
November 2012 Br J Cardiol 2012;19:160
First UK operation for HF with nerve-stimulating implant The UK’s first operation to tackle heart failure (HF) with a novel nerve-stimulating device was performed recently at Glenfield Hospital, Leicester. The operation was part of the INOVATE-HF clinical trial, a global investigation to determine the safety and efficacy of the an implantable electrical stimulation device (CardioFit,® BioControl Medical), designed to improve heart function in patients with HF. The study will evaluate the system’s ability to reduce hospitalisation and death among patients with HF, while also exploring whether combined treatment with the system and pres
September 2010 Br J Cardiol 2010;17:209
BJ Cardio Staff
New NT-proBNP test Roche Diagnostics has announced the launch of a new NT-proBNP+ test, which it says can give a result in under 15 minutes when tested on its cobas h232 near-patient testing meter. In addition, the test has an extended measuring range (60 – 9000pg/ml). The test can serve as an aid in the diagnosis of suspected heart failure, in the monitoring of compensated left ventricular dysfunction and in the risk stratification of patients with acute coronary symptoms. Recent recommendations of a consensus group (Br J Cardiol 2010;17:76-80) highlight the importance of B-type natriuretic peptide (NP) testing for heart failure. NP testi